Actinium to Host Webinar on Iomab-ACT CAR T-Cell Therapy Trial and Market Potential

Actinium Pharmaceuticals, Inc., a leading company in the field of Antibody Radiation Conjugates (ARCs) and targeted radiotherapies, has scheduled a Key Opinion Leader (KOL) webinar for Monday, May 20, 2024, at 8:00 AM ET. The webinar will focus on discussing the Iomab-ACT commercial CAR T-cell trial being conducted at the University of Texas Southwestern (UTSW). Key participants include Dr. Farrukh Awan, Professor of Medicine in the Division of Hematology Oncology at UTSW, who will join Actinium's management team. Dr. Awan, an expert in leukemia and lymphoma treatments, CAR-T therapy, and bone marrow transplantation, will serve as the principal investigator for this study.

The Iomab-ACT trial, designed to facilitate CAR T-cell therapy conditioning, is significant as it represents the first instance of studying a targeted radiotherapy conditioning agent with FDA-approved CAR T-cell therapy. Previously, Iomab-ACT has been examined in conjunction with an investigational CD19 targeting CAR-T cell therapy developed by Memorial Sloan Kettering Cancer Center (MSKCC) under a National Institutes of Health funded grant. The upcoming trial at UTSW will further explore its efficacy and potential commercial use.

Iomab-ACT is an ARC designed to target CD45, a marker present on blood cancer cells and immune cells. It aims to provide conditioning before cell and gene therapies such as CAR T-cell therapy, potentially replacing the current non-targeted chemotherapy methods. There are already six FDA-approved CAR-T cell therapies that collectively achieved over $3.5 billion in sales in 2023, treating patients with leukemia, lymphoma, and multiple myeloma.

In February 2024, Actinium shared promising results from its ongoing phase 1 trial of Iomab-ACT as conditioning for CD19 CAR-T therapy in patients with relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) or Diffuse Large B-cell Lymphoma (DLBCL). The results were presented at the Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR. Notably, none of the patients developed immune effector cell-associated neurotoxicity syndrome (ICANS), a significant safety measure, and there were minimal cases of Cytokine Release Syndrome (CRS). ICANS, which affects 25% or more of patients treated with approved CAR T-cell products, along with other toxicities, was notably absent in this trial.

Furthermore, Iomab-ACT demonstrated transient depletion of peripheral blood lymphocytes and monocytes, persistence of CAR T-cells for up to 8 weeks, and minimal non-hematologic toxicities. This indicates a strong potential for improving conditioning processes in cellular therapies.

The potential market for Iomab-ACT is considerable. With the rapid expansion of CAR-T and gene therapies, the patient population in the U.S. is expected to nearly double, reaching approximately 93,000 by 2030. The CAR-T market size is projected to grow at a compound annual growth rate (CAGR) of around 11% over the next several years. Given that all patients undergoing cell and gene therapies require some form of conditioning, Iomab-ACT's targeted approach presents a significant commercial opportunity.

Actinium Pharmaceuticals continues to develop Iomab-ACT and other advanced pipeline candidates like Iomab-B and Actimab-A, aiming to improve survival outcomes for patients who have not benefited from existing oncology therapies. Holding over 230 patents and applications, Actinium is well-positioned to advance its innovative treatments.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!